Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H34N2O3 |
Molecular Weight | 410.5491 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCOC1=CC=C2C(=C1)C(=O)C3=C2C=CC(OCCN(CC)CC)=C3
InChI
InChIKey=MPMFCABZENCRHV-UHFFFAOYSA-N
InChI=1S/C25H34N2O3/c1-5-26(6-2)13-15-29-19-9-11-21-22-12-10-20(30-16-14-27(7-3)8-4)18-24(22)25(28)23(21)17-19/h9-12,17-18H,5-8,13-16H2,1-4H3
DescriptionSources: https://www.rlsnet.ru/mnn_index_id_2731.htmCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27809794 | https://www.ncbi.nlm.nih.gov/pubmed/24841903
Sources: https://www.rlsnet.ru/mnn_index_id_2731.htm
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27809794 | https://www.ncbi.nlm.nih.gov/pubmed/24841903
Tilorone (trade names Amixin, Lavomax and others) is the first recognized synthetic, small molecular weight compound that is an orally active interferon inducer. Tilorone induces the formation of interferons (alpha, beta, gamma) by intestinal epithelial cells, hepatocytes, T-lymphocytes, and granulocytes. After ingestion, the maximum production of interferon is determined in the sequence of the intestine - liver - blood after 4-24 hours. Activates the stem cells of the bone marrow, stimulates humoral immunity, increases the production of IgM, IgA, IgG, affects the antibody formation, reduces the degree of immunosuppression, restores the ratio of T-helperers / T-suppressors. The mechanism of antiviral action is associated with the inhibition of translation of virus-specific proteins in infected cells, thereby suppressing the replication of the virus. Effective against influenza viruses and viruses that cause ARVI, hepato- and herpesviruses, incl. CMV and others. The mechanism of antiviral action is associated with the inhibition of translation of virus-specific proteins in infected cells, thereby suppressing the replication of the virus.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0032607 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26633340 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Amixin Approved UseUnknown |
|||
Primary | Amixin Approved UseUnknown |
|||
Primary | Amixin Approved UseUnknown |
|||
Primary | Amixin Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Antiviral activity and induction of interferon-like substance by quinacrine and acranil. | 1973 May |
|
Bis-basic-substituted polycyclic aromatic compounds. A new class of antiviral agents. 3. 2,7-Bis(aminoacyl)fluorenes and -fluorenones. | 1974 Aug |
|
Antiviral and interferon-inducing properties of interferon inducers administered with prostaglandins. | 1980 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.rlsnet.ru/tn_index_id_1526.htm
Treatment of viral hepatitis A - on the first day of 125 mg 2 times, then - 125 mg after 48 hours. The course - 1.25 g (10 tables.).
Treatment of acute hepatitis B - the first two days of 125 mg, then 125 mg after 48 hours, the course of treatment - 2 g (16 table). With prolonged course of hepatitis B, 125 mg twice a day on the first day, then 125 mg after 48 hours. The course of treatment is 2.5 g (20 tablets).
Acute hepatitis C - 125 mg / day for the first 2 days of treatment, then 125 mg after 48 hours. The course of treatment is 2.5 g (20 tablets).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24841903
MTS assays were performed to measure the antiproliferative effect of tilorone treatment. Tilorone dihydrochloride
(Sigma-Aldrich) was stored as a 10 mM stock solution in DMSO at -20˚C. One thousand PC3 cells were plated in 96-well plates containing 100 μl complete RPMI media. At circa 50% confluence, tilorone dihydrochloride was administered.
For experiments the compound was diluted in complete RPMI media to obtain the desired final concentration. After treatment for 72 h (tilorone monotherapy), MTS reagent was added, and absorption at 490 nm was determined using a SoftMax Pro plate reader.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/18/2069
Created by
admin on Fri Dec 15 15:59:51 GMT 2023 , Edited by admin on Fri Dec 15 15:59:51 GMT 2023
|
||
|
NCI_THESAURUS |
C281
Created by
admin on Fri Dec 15 15:59:51 GMT 2023 , Edited by admin on Fri Dec 15 15:59:51 GMT 2023
|
||
|
WHO-ATC |
J05AX19
Created by
admin on Fri Dec 15 15:59:51 GMT 2023 , Edited by admin on Fri Dec 15 15:59:51 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000077218
Created by
admin on Fri Dec 15 15:59:51 GMT 2023 , Edited by admin on Fri Dec 15 15:59:51 GMT 2023
|
PRIMARY | |||
|
SUB11057MIG
Created by
admin on Fri Dec 15 15:59:51 GMT 2023 , Edited by admin on Fri Dec 15 15:59:51 GMT 2023
|
PRIMARY | |||
|
C73335
Created by
admin on Fri Dec 15 15:59:51 GMT 2023 , Edited by admin on Fri Dec 15 15:59:51 GMT 2023
|
PRIMARY | |||
|
2941
Created by
admin on Fri Dec 15 15:59:51 GMT 2023 , Edited by admin on Fri Dec 15 15:59:51 GMT 2023
|
PRIMARY | |||
|
DTXSID1045958
Created by
admin on Fri Dec 15 15:59:51 GMT 2023 , Edited by admin on Fri Dec 15 15:59:51 GMT 2023
|
PRIMARY | |||
|
27591-97-5
Created by
admin on Fri Dec 15 15:59:51 GMT 2023 , Edited by admin on Fri Dec 15 15:59:51 GMT 2023
|
PRIMARY | |||
|
147347
Created by
admin on Fri Dec 15 15:59:51 GMT 2023 , Edited by admin on Fri Dec 15 15:59:51 GMT 2023
|
PRIMARY | |||
|
m10867
Created by
admin on Fri Dec 15 15:59:51 GMT 2023 , Edited by admin on Fri Dec 15 15:59:51 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL47298
Created by
admin on Fri Dec 15 15:59:51 GMT 2023 , Edited by admin on Fri Dec 15 15:59:51 GMT 2023
|
PRIMARY | |||
|
TILORONE
Created by
admin on Fri Dec 15 15:59:51 GMT 2023 , Edited by admin on Fri Dec 15 15:59:51 GMT 2023
|
PRIMARY | |||
|
O6W7VEW6KS
Created by
admin on Fri Dec 15 15:59:51 GMT 2023 , Edited by admin on Fri Dec 15 15:59:51 GMT 2023
|
PRIMARY | |||
|
5475
Created by
admin on Fri Dec 15 15:59:51 GMT 2023 , Edited by admin on Fri Dec 15 15:59:51 GMT 2023
|
PRIMARY | |||
|
D013994
Created by
admin on Fri Dec 15 15:59:51 GMT 2023 , Edited by admin on Fri Dec 15 15:59:51 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)